-
Researchers say some Mexican pharmacies that cater to U.S. tourists and medical travelers are selling medications that look safe but are laced with deadly fentanyl and methamphetamines.
-
The removal announcement from Covis Pharma comes roughly four years after Makena failed to show a benefit in helping mothers carry pregnancies to term.
-
The company is tapping into a red-hot market for drugs that address obesity with the purchase of telehealth operator Sequence, which can prescribe medications such as Ozempic, Wegovy and Trulicity.
-
The FDA has long blocked the importation of cheap medicine, agreeing with pharmaceutical manufacturers that it opens the door to opioids. The agency’s own data shows that rarely happens.
-
Drug pricing experts predict the move will help other initiatives to bring lower-cost insulin to market and maintain pressure on Eli Lilly to keep its prices down.
-
The FDA has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.
-
Lilly said it will cut the list prices for its most commonly prescribed insulin, Humalog, and for another insulin, Humulin, by 70% or more in the fourth quarter, which starts in October.
-
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
-
The billionaire entrepreneur, Dallas Mavericks owner and "Shark Tank" star is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.
-
Twitter has been a hotbed for the insulin access movement and activism surrounding other medical conditions - helping propel concern about the prices into policy. Can it continue to win with hashtags?